{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:22:42Z","timestamp":1780590162805,"version":"3.54.1"},"reference-count":0,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2016,1,4]],"date-time":"2016-01-04T00:00:00Z","timestamp":1451865600000},"content-version":"vor","delay-in-days":15009,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[1974,12]]},"abstract":"<jats:p>Maximum plasma levels of diphenhydramine in normal subjects ranged from 81 to 159 ng\/ml in 2 to 4 hr after single 100 mg oral doses, with an estimated half\u2010life of 7 hr. Multiple oral doses of 50 mg four times daily for 3 days produced mean peak levels of approximately 110 ng\/ml by the second day, with an estimated half\u2010life of 6 hr. Total amine levels were 50% to 100% higher, due to the presence of N\u2010dealkylated metabolites. Single 100 mg oral doses of diphenhydramine also produced a progressive increase in the plasma levels of acidic metabolites over a 24 hr period, reaching values 10 times those of the maximum diphenhydramine levels. Urinary excretion of total diphenhydramine metabolites represented about 64% of the dose in single dose studies, and 49% after multiple doses. These observations are consistent with earlier studies on the metabolic disposition of labeled diphenhydramine in laboratory animals.<\/jats:p>","DOI":"10.1002\/cpt19741661066","type":"journal-article","created":{"date-parts":[[2016,1,5]],"date-time":"2016-01-05T01:36:55Z","timestamp":1451957815000},"page":"1066-1076","source":"Crossref","is-referenced-by-count":45,"title":["Metabolic disposition of diphenhydramine"],"prefix":"10.1111","volume":"16","author":[{"given":"A. J.","family":"Glazko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. A.","family":"Dill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. M.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. C.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. I.","family":"Ogilvie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,1,4]]},"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt19741661066","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt19741661066","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt19741661066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:32:39Z","timestamp":1699363959000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt19741661066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1974,12]]},"references-count":0,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1974,12]]}},"alternative-id":["10.1002\/cpt19741661066"],"URL":"https:\/\/doi.org\/10.1002\/cpt19741661066","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[1974,12]]}}}